These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30508592)

  • 41. Treatment utilization among persons with opioid use disorder in the United States.
    Wu LT; Zhu H; Swartz MS
    Drug Alcohol Depend; 2016 Dec; 169():117-127. PubMed ID: 27810654
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial.
    Ahmadi J; Jahromi MS; Ehsaei Z
    Trials; 2018 Aug; 19(1):462. PubMed ID: 30157924
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
    McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD
    J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review.
    Kiluk BD; Kleykamp BA; Comer SD; Griffiths RR; Huhn AS; Johnson MW; Kampman KM; Pravetoni M; Preston KL; Vandrey R; Bergeria CL; Bogenschutz MP; Brown RT; Dunn KE; Dworkin RH; Finan PH; Hendricks PS; Houtsmuller EJ; Kosten TR; Lee DC; Levin FR; McRae-Clark A; Raison CL; Rasmussen K; Turk DC; Weiss RD; Strain EC
    JAMA Psychiatry; 2023 Jan; 80(1):84-92. PubMed ID: 36449315
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.
    Connock M; Juarez-Garcia A; Jowett S; Frew E; Liu Z; Taylor RJ; Fry-Smith A; Day E; Lintzeris N; Roberts T; Burls A; Taylor RS
    Health Technol Assess; 2007 Mar; 11(9):1-171, iii-iv. PubMed ID: 17313907
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
    Albayaty M; Linden M; Olsson H; Johnsson M; Strandgården K; Tiberg F
    Adv Ther; 2017 Feb; 34(2):560-575. PubMed ID: 28070862
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Criminal behavior in opioid-dependent patients before and during maintenance therapy: 6-year follow-up of a nationally representative cohort sample.
    Soyka M; Träder A; Klotsche J; Haberthür A; Bühringer G; Rehm J; Wittchen HU
    J Forensic Sci; 2012 Nov; 57(6):1524-30. PubMed ID: 22845057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
    Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
    Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder.
    Schmith VD; Curd L; Lohmer LRL; Laffont CM; Andorn A; Young MA
    Clin Pharmacol Ther; 2019 Sep; 106(3):576-584. PubMed ID: 30801681
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of early childhood trauma on retention and phase advancement in an outpatient buprenorphine treatment program.
    Kumar N; Stowe ZN; Han X; Mancino MJ
    Am J Addict; 2016 Oct; 25(7):542-8. PubMed ID: 27629823
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluating comparative effectiveness of psychosocial interventions for persons receiving opioid agonist therapy for opioid use disorder: protocol for a systematic review.
    Rice DB; Hutton B; Poulin P; Sproule BA; Wolfe D; Moher D; Thavorn K; Garber G; Taha S; Porath A; Willows M; Esmaeilisaraji L; Yazdi F; Shea B; Skidmore B; Corace K
    BMJ Open; 2018 Oct; 8(10):e023902. PubMed ID: 30341139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder.
    Golan OK; Totaram R; Perry E; Fortson K; Rivera-Atilano R; Entress R; Golan M; Andraka-Christou B; Whitaker D; Pigott T
    Drug Alcohol Depend; 2022 Jun; 235():109445. PubMed ID: 35430522
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
    Manhapra A; Agbese E; Leslie DL; Rosenheck RA
    Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Urine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use Disorder.
    Williams AR; Rowe C; Gallagher R; Aronowitz SV; Diamond-Reivich J; Bisaga A
    JAMA Health Forum; 2023 Jul; 4(7):e232247. PubMed ID: 37505489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years.
    Nordt C; Vogel M; Dey M; Moldovanyi A; Beck T; Berthel T; Walter M; Seifritz E; Dürsteler KM; Herdener M
    Addiction; 2019 Jan; 114(1):103-111. PubMed ID: 30209840
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Abstinence-contingent recovery housing and reinforcement-based treatment following opioid detoxification.
    Tuten M; DeFulio A; Jones HE; Stitzer M
    Addiction; 2012 May; 107(5):973-82. PubMed ID: 22151478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.